(RXRX) - Analyzing Recursion Pharmaceuticals's Short InterestBenzinga • about 12 hours ago
read more...
Share to Feed
AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029 PR Newswire VANCOUVER, BC, April 25, 2024 USA News Group...
Latest Ratings for RXRX
DateFirmActionFromTo Mar 2022SVB LeerinkDowngradesOutperformMarket Perform Dec 2021SVB LeerinkMaintainsOutperform Sep 2021BerenbergInitiates Coverage OnBuy
View More...
Related Stocks: RXRX...
SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
For the last three days, A.I.dvisor has detected that RXRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
In trading on Tuesday, shares of Recursion Pharmaceuticals Inc (RXRX) crossed below their 200 day moving average of 9.32, changing hands as low as 8.67 per share. Recursion Pharmaceuticals...
Poseida Therapeutics (NASDAQ:PSTX Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX Get Free Report) are both medical companies, but which is the superior investment? We...
Provides progress updates in support of long-term commitments focused on reducing greenhouse gas emissions, improving workforce diversity and accelerating community impact.SALT LAKE CITY, March 26...
Related Stocks: RXRX...